Compare CHCI & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHCI | SWKH |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Building operators | Diversified Financial Services |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.9M | 198.4M |
| IPO Year | 2004 | N/A |
| Metric | CHCI | SWKH |
|---|---|---|
| Price | $16.71 | $16.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 15.5K | ★ 52.9K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $62,861,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $177.67 | ★ $9.18 |
| Revenue Growth | ★ 22.55 | N/A |
| 52 Week Low | $9.00 | $13.17 |
| 52 Week High | $19.72 | $17.90 |
| Indicator | CHCI | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 32.19 |
| Support Level | $15.19 | $14.69 |
| Resistance Level | $17.42 | $17.08 |
| Average True Range (ATR) | 0.86 | 0.37 |
| MACD | -0.49 | -0.05 |
| Stochastic Oscillator | 11.77 | 12.06 |
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.